C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.000
+0.080 (2.74%)
Apr 20, 2026, 1:55 PM EDT - Market open
C4 Therapeutics Revenue
In the year 2025, C4 Therapeutics had annual revenue of $35.95M with 1.02% growth. C4 Therapeutics had revenue of $11.02M in the quarter ending December 31, 2025, with 193.06% growth.
Revenue (ttm)
$35.95M
Revenue Growth
+1.02%
P/S Ratio
7.93
Revenue / Employee
$345,644
Employees
104
Market Cap
292.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.95M | 363.00K | 1.02% |
| Dec 31, 2024 | 35.58M | 4.49M | 14.43% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
| Dec 31, 2018 | 19.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 72.76M |
| Orchestra BioMed Holdings | 33.48M |
| Alector | 21.05M |
| AC Immune | 4.51M |
| SAB Biotherapeutics | 114.70K |
CCCC News
- 11 days ago - C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion - Reuters
- 11 days ago - C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) - GlobeNewsWire
- 26 days ago - C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 5 weeks ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire